Poehling Capital Management’s Gilead Sciences GILD Stock Holding History

Poehling Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25,192	Closed	-$1.64M	–	103
2019 Q4	$1.64M	Sell	25,192 -5,615	-18%	-$366K	1.07%	31
2019 Q3	$1.95M	Sell	30,807 -740	-2%	-$48.4K	1.43%	19
2019 Q2	$2.13M	Buy	31,547 +1,390	+5%	+$91.4K	1.43%	20
2019 Q1	$1.96M	Sell	30,157 -825	-3%	-$54.8K	1.43%	20
2018 Q4	$1.94M	Sell	30,982 -8,160	-21%	-$570K	1.87%	13
2018 Q3	$3.02M	Buy	39,142 +10,230	+35%	+$773K	2.14%	11
2018 Q2	$2.05M	Sell	28,912 -12,225	-30%	-$863K	1.79%	12
2018 Q1	$3.1M	Sell	41,137 -420	-1%	-$33.4K	2.5%	3
2017 Q4	$2.98M	Buy	+41,557	New	+$3.16M	2.53%	4

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Poehling Capital Management's GILD Position: Q1 2020 in Review

Poehling Capital Management sold out of Gilead Sciences (GILD) in Q1 2020, closing a stake of 25,192 shares — an estimated $1.64M sold.

Poehling Capital Management first reported a position in GILD in Q4 2017 and held it in 9 quarters. The position peaked at $3.1M in Q1 2018. 1,643 funds tracked by Wall St. Rank hold GILD as of Q1 2020.

Poehling Capital Management reported no remaining Gilead Sciences position as of Q1 2020 after selling out during the quarter.
Poehling Capital Management sold 25,192 Gilead Sciences shares in Q1 2020, an estimated $1.64M.
Poehling Capital Management first reported a position in Gilead Sciences in Q4 2017 and held it in 9 quarters.
Poehling Capital Management's Gilead Sciences position peaked at $3.1M in Q1 2018.
1,643 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2020.

Based on Poehling Capital Management's 13F filing for Q1 2020, filed 6 May 2020.